Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novocure, FDA
Novocure nets FDA approval for Tumor Treating Fields in metastatic lung cancer
Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small cell lung cancer—which the company described as the first tre | Novocure described its Tumor Treating Fields therapy as the first of its kind for the aggressive cancer,
Novocure wins FDA approval for electric field device in lung cancer
Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.
NovoCure scoops FDA approval on wearable for metastatic cancer treatment
NovoCure’s Optune Lua, a wearable indicated for patients with metastatic non-small cell lung cancer has received approval from the US FDA.
Novacure’s Wearable Lung Cancer Treatment Device, Optune Lua, Receives FDA Approval
The FDA has granted approval for Novocure‘s wearable medical device, Optune Lua, designed to treat advanced non-small cell lung cancer (NSCLC).
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for concurrent use with PD-1/PD-L1 i
Novocure wins FDA nod for lung cancer treatment wearable
Novocure announced on Tuesday that the FDA treated its Optune Lua wearable device for treating metastatic non-small cell lung cancer.
Novocure shares surge on cancer treatment approval, and other movers
Novocure shares are surging 35% after the company said that the [Food and Drug Administration had approved Optune Lua](
NovoCure’s Growth Potential Boosted by FDA Approval and Market Expansion
Leerink Partners analyst Jonathan Chang maintained a Buy rating on NovoCure (NVCR – Research Report) yesterday and set a price target of
Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction.
Novocure stock advanced, but pulled back from massive gains after the FDA signed off on its cancer treatment device.
3d
NovoCure: There Is Still More Upside
On October 15th, NovoCure Limited received FDA approval of its lung cancer treatment. Read why I upgrade NVCR stock from buy ...
STAT
3d
A controversial approval for Novocure’s device
The FDA yesterday the approval of Novocure’s Optune device to include the treatment of metastatic non-small cell lung cancer.
3d
FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients
Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non-small cell lung ...
3d
on MSN
These Stocks Are Moving the Most Today: ASML, Nvidia, United Airlines, J.B. Hunt, DJT, Novocure, Morgan Stanley, and More
ASML extends losses after cutting sales guidance, Nvidia stock edges higher, and third-quarter adjusted earnings at United ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Advanced Micro Devices
Optune Lua
Nvidia
ASML Holding
Food and Drug Administration
Feedback